Adaptimmune Therapeutics (473A) Stock Overview

Engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. More details

473A fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Does not have a meaningful market cap (€8M)

Has less than 1 year of cash runway

473A Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Adaptimmune Therapeutics plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Adaptimmune Therapeutics
Historical stock prices
Current Share Price	US$0.013
52 Week High	US$0.034
52 Week Low	US$0.0085
Beta	1.76
1 Month Change	0%
3 Month Change	-24.24%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-63.24%

Recent updates

Shareholder Returns

	473A	DE Biotechs	DE Market
7D	0%	-1.6%	1.5%
1Y	n/a	-5.1%	3.3%

Return vs Industry: Insufficient data to determine how 473A performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 473A performed against the German Market.

Price Volatility

Is 473A's price volatile compared to industry and market?
473A volatility
473A Average Weekly Movement	35.8%
Biotechs Industry Average Movement	9.0%
Market Average Movement	5.9%
10% most volatile stocks in DE Market	13.1%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: 473A's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 473A's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2008	506	Chris Hill	www.adaptimmune.com

Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Adaptimmune Therapeutics plc Fundamentals Summary

How do Adaptimmune Therapeutics's earnings and revenue compare to its market cap?
473A fundamental statistics
Market cap	€8.00m
Earnings (TTM)	-€67.30m
Revenue (TTM)	€5.11m

1.6x

P/S Ratio

-0.1x

P/E Ratio

Is 473A overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
473A income statement (TTM)
Revenue	US$5.92m
Cost of Revenue	US$0
Gross Profit	US$5.92m
Other Expenses	US$83.93m
Earnings	-US$78.01m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.29
Gross Margin	100.00%
Net Profit Margin	-1,316.78%
Debt/Equity Ratio	0%

How did 473A perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/16 06:27
End of Day Share Price	2026/05/21 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Adaptimmune Therapeutics plc is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ying Huang	BofA Global Research
Mohit Bansal	Citigroup Inc
Reni Benjamin	Raymond James & Associates

Adaptimmune Therapeutics plcMUN:473A Stock Report